HRT and Heart Disease: The Timing Hypothesis
SaveHormone therapy is not used to prevent heart disease, but when it starts matters. Estrogen begun near menopause — under 60 or within 10 years — looks neutral or slightly favorable, while starting a decade later can raise cardiovascular risk. This pattern, the timing hypothesis, comes from trials like ELITE.
Last updated: July 2026
Continue in Claude
Open a chat with this article’s link already in the message, and keep asking questions there. Claude reads the article and its sources; nothing about you is included.
The button opens the Claude desktop app and fills in the message for you to review before sending. No desktop app, or reading on a phone? Copy the prompt and paste it into any AI.
What is the timing hypothesis?
The timing hypothesis holds that estrogen's effect on arteries depends on how healthy those arteries already are when treatment begins. Near menopause, arteries are relatively clear, and estrogen may help keep them that way; a decade or more later, established plaque may respond to estrogen very differently. According to the North American Menopause Society, this is why hormone therapy is not recommended to prevent heart disease, yet appears reasonably safe for the heart when started early for symptoms — generally in women under 60 or within 10 years of menopause 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.Menopause society position that hormone therapy is not indicated for cardiovascular prevention but is reasonably safe for the heart when started in women under 60 or within 10 years of menopause.. It reframes an old worry into a question of when, not simply whether. The broader hormone therapy decision sits on top of this timing logic.
What did the ELITE and KEEPS trials show?
Two randomized trials tested estrogen in early versus late menopause and found the artery effects diverged. In ELITE, estradiol slowed the thickening of carotid artery walls in women who were less than 6 years past menopause, but not in women 10 or more years out 2Ref 2Hodis HN, Mack WJ, Henderson VW, et al. (2016).Vascular effects of early versus late postmenopausal treatment with estradiol.The ELITE randomized trial showing estradiol slowed carotid intima-media thickening in women less than 6 years past menopause but not in those 10 or more years out.. In KEEPS, hormone therapy in recently menopausal women did not significantly change measures of atherosclerosis over about 4 years, though it improved several risk factors 3Ref 3Harman SM, Black DM, Naftolin F, et al. (2014).Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.The KEEPS trial showing hormone therapy in recently menopausal women did not significantly change atherosclerosis imaging outcomes over about 4 years while improving risk factors.. Neither trial proves hormones prevent heart attacks, and neither showed early-start harm. Together they anchor the idea that starting near menopause is, at worst, artery-neutral — a very different message from the one that dominated headlines two decades ago.
Why did the WHI first suggest harm?
The Women's Health Initiative reported more coronary events in women taking estrogen plus progestin, which alarmed clinicians for years. That trial enrolled women who were, on average, about 63 years old and often more than a decade past menopause, and in that older group estrogen plus progestin modestly raised coronary heart disease risk 4Ref 4Manson JE, Hsia J, Johnson KC, et al. / Women's Health Initiative Investigators (2003).Estrogen plus progestin and the risk of coronary heart disease.The WHI coronary analysis in an older population (average age about 63) in which estrogen plus progestin modestly raised coronary heart disease risk.. A later Cochrane review made the timing pattern explicit: hormone therapy started more than 10 years after menopause raised stroke and clot risk with no heart benefit, while women who started within 10 years had lower coronary heart disease — roughly half in that analysis — and lower mortality 5Ref 5Boardman HMP, Hartley L, Eisinga A, et al. (2015).Hormone therapy for preventing cardiovascular disease in post-menopausal women.Cochrane review showing hormone therapy started within 10 years of menopause was associated with lower coronary heart disease and mortality, while later initiation raised stroke and clot risk.. The lesson was less about the drug than about the age at which it began. Managing traditional risk factors, including through diet that lowers heart risk, remains the real prevention tool.
Does the menopause transition itself change heart risk?
Cardiovascular risk in women accelerates during the menopause transition, independent of any hormone therapy. According to an American Heart Association statement, the years around menopause — typically between ages 45 and 55 — bring unfavorable shifts in cholesterol, body fat, and blood vessels that raise lifetime heart risk 6Ref 6El Khoudary SR, et al. (American Heart Association) (2020).Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association.American Heart Association statement that cardiovascular risk factors worsen across the menopause transition (roughly ages 45 to 55) independent of hormone therapy.. That is why prevention advice centers on blood pressure, lipids, activity, and not smoking rather than on hormones. Symptoms of the menopause transition, such as hot flashes and night sweats, may even flag women who warrant closer cardiovascular attention. Heart risk here is a story of the whole transition, not of a single medication.
When a clinician weighs hormones and your heart
A clinician can place your personal heart risk, symptoms, and timing into one picture. A gynecologist or menopause clinician, sometimes alongside primary care or cardiology, can assess blood pressure, cholesterol, and history, then judge whether hormone therapy is reasonable for symptoms — without treating it as heart protection. The same visit is a natural moment to look at overall prevention and at related questions such as the effect of hormones on the brain. Gale can help you assemble your risk factors and questions before that conversation.
Common questions
Related
Menopause & midlife
Starting HRT After 60: The Timing QuestionMenopause & midlife
HRT and Dementia Risk: What Studies ShowMenopause & midlife
HRT and Breast Cancer: The Absolute Numbers
Say it back
How would you explain this to someone you love?
Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.
Heart symptoms that need attention
- —Chest pressure, pain spreading to the arm or jaw, or sudden shortness of breath is a reason to call 911 right away
- —New or worsening breathlessness, palpitations, or fainting is a reason to seek same-day clinician review
- —Leg swelling, warmth, or calf pain that could signal a clot is a reason to seek prompt medical review
- —A personal history of heart disease or stroke is a reason to review any hormone plan with your clinician
This article is general health education, not medical advice. Whether hormone therapy is reasonable given your heart risk is a decision for a gynecologist, menopause clinician, or your primary care or cardiology team.
References
- 1.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓Menopause society position that hormone therapy is not indicated for cardiovascular prevention but is reasonably safe for the heart when started in women under 60 or within 10 years of menopause.
- 2.Hodis HN, Mack WJ, Henderson VW, et al. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine. doi:10.1056/NEJMoa1505241 ✓The ELITE randomized trial showing estradiol slowed carotid intima-media thickening in women less than 6 years past menopause but not in those 10 or more years out.
- 3.Harman SM, Black DM, Naftolin F, et al. (2014). Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Annals of Internal Medicine. doi:10.7326/M14-0353 ✓The KEEPS trial showing hormone therapy in recently menopausal women did not significantly change atherosclerosis imaging outcomes over about 4 years while improving risk factors.
- 4.Manson JE, Hsia J, Johnson KC, et al. / Women's Health Initiative Investigators (2003). Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine. doi:10.1056/NEJMoa030808 ✓The WHI coronary analysis in an older population (average age about 63) in which estrogen plus progestin modestly raised coronary heart disease risk.
- 5.Boardman HMP, Hartley L, Eisinga A, et al. (2015). Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD002229.pub4 ✓Cochrane review showing hormone therapy started within 10 years of menopause was associated with lower coronary heart disease and mortality, while later initiation raised stroke and clot risk.
- 6.El Khoudary SR, et al. (American Heart Association) (2020). Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. doi:10.1161/CIR.0000000000000912 ✓American Heart Association statement that cardiovascular risk factors worsen across the menopause transition (roughly ages 45 to 55) independent of hormone therapy.
6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy